Biocon Limited CC-May26.pdf · 2026-05-08
This is Avnish Burman from Vaikarya. Shreehas, sir, just one question for you. In March, I think we saw some draft guidelines coming from the FDA, which talked about significantly reducing the R&D cost to get like new biosimilars in the market. So , I just wanted your opinion on how that impacts, one, Biocon's existing products, commercialized products; and second, the pipeline?
So, I understand it being beneficial for Biocon in terms of the products that you are still yet to bring in the market. But what about the products where Biocon has a good position in the market? I mean, where you are the incumbent and you might be facing some incremental challenges in those products?